Other

Labopharm Inc.

Histapharm Inc.

Karici Diagnostics Inc.

Lenaerts, Vincent

Chouinard, Francois

Mateescu, Mircea A.

Ispas-szabo, Pompilia

Pompilia Ispas-Szabo

Mircea Alexandru Mateescu

Vincent Lenaerts

Canh Le Tien

Mircea-Alexandru Mateescu

Francois Chouinard

Rodolfo Federico

Carmen Calinescu

Le Tien Canh

Mihaela Friciu

Bruno Mondovi

Mircea A Mateescu

The present disclosure describes compositions for intestinal delivery of enzyme formulations and methods of treating health problems with these formulations. More specifically, the enzyme formulations include at least one histaminase and various methods of treatment of physical conditions, such as inflammation, allergy, histamine intolerance, and intestinal cancer.

Oral enzyme compositions for intestinal delivery

The present document describes a composition for sustained, targeted or sustained and targeted delivery of an active ingredient which includes a complex formed between a carboxyl substituted polymer and a lipid. The present document also describes dosage forms containing the composition, and an active ingredient, and methods of using the same for the treatment of diseases.

Complex containing carboxyl substituted starch and lipid for delayed delivery of active ingredients

The present invention relates to a solid slow release oral pharmaceutical dosage unit resistant to amylase which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical agent, an optional polysaccharide or polyol, and high amylose starch, wherein the cross-linking of the high amylose starch has been carried out with a cross-linking agent with from about 0.1 g to about 40 g of cross-linking agent per 100 g of high amylose starch. In a preferred embodiment of the invention, the high amylose starch is modified with a functional group-attaching reagent that covalently bonds functional groups thereto.

Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents

The present invention is concerned with a solid slow release oral pharmaceutical dosage unit resistant to amylase which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical product, an optional polysaccharide or polyol, and cross-linked high amylose starch, wherein the cross-linking of the high amylose starch has been carried out with a covalent or non-covalent cross-linking agent with from about 0.1 g to about 30 g of cross-linking agent per 100 g of high amylose starch.

Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds

Growing community of inventors

Longueuil, Canada

Pompilia Ispas-Szabo